OA
AWH

Operose Advisors’s Aspira Women's Health Inc. Common Stock AWH Stock Holding History

Operose Advisors’s Portfolio AWH Stock Details AWH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed -$94 – 424
2025
Q1 		$94 Hold
1,000
– – ﹤0.01% 384
2024
Q4 		$705 Hold
1,000
– – ﹤0.01% 411
2024
Q3 		$810 Hold
1,000
– – ﹤0.01% 596
2024
Q2 		$1.49K Hold
1,000
– – ﹤0.01% 547
2024
Q1 		$3.1K Hold
1,000
– – ﹤0.01% 571
2023
Q4 		$4.08K Hold
1,000
– – ﹤0.01% 534
2023
Q3 		$5.36K Hold
1,000
– – ﹤0.01% 653
2023
Q2 		$3.31K Hold
1,000
– – ﹤0.01% 322
2023
Q1 		$5.49K Hold
1,000
– – ﹤0.01% 292
2022
Q4 		$4.99K Hold
1,000
– – ﹤0.01% 319
2022
Q3 		$6K Hold
1,000
– – ﹤0.01% 302
2022
Q2 		$9K Hold
1,000
– – 0.01% 248
2022
Q1 		$16K Hold
1,000
– – 0.01% 231
2021
Q4 		$27K Buy
+1,000
New +$37.9K 0.02% 183

Other funds holding AWH

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Operose Advisors's AWH Position: Q2 2025 in Review

Operose Advisors sold out of Aspira Women's Health Inc. Common Stock (AWH) in Q2 2025, closing a stake of 1,000 shares — an estimated $94 sold.

Operose Advisors first reported a position in AWH in Q4 2021 and held it in 14 quarters. The position peaked at $27K in Q4 2021. 2 funds tracked by Wall St. Rank hold AWH as of Q2 2025.

  • Operose Advisors reported no remaining Aspira Women's Health Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • Operose Advisors sold 1,000 Aspira Women's Health Inc. Common Stock shares in Q2 2025, an estimated $94.
  • Operose Advisors first reported a position in Aspira Women's Health Inc. Common Stock in Q4 2021 and held it in 14 quarters.
  • Operose Advisors's Aspira Women's Health Inc. Common Stock position peaked at $27K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Aspira Women's Health Inc. Common Stock as of Q2 2025.

Based on Operose Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.